28,146 Shares in PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Acquired by Virtu Financial LLC

Virtu Financial LLC purchased a new stake in shares of PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) during the third quarter, Holdings Channel.com reports. The firm purchased 28,146 shares of the company’s stock, valued at approximately $42,000.

Other large investors have also recently made changes to their positions in the company. Assenagon Asset Management S.A. grew its holdings in shares of PMV Pharmaceuticals by 267.2% during the 2nd quarter. Assenagon Asset Management S.A. now owns 260,028 shares of the company’s stock valued at $421,000 after purchasing an additional 189,214 shares during the last quarter. Evoke Wealth LLC purchased a new stake in PMV Pharmaceuticals during the second quarter valued at about $102,000. Cubist Systematic Strategies LLC grew its stake in shares of PMV Pharmaceuticals by 570.8% during the second quarter. Cubist Systematic Strategies LLC now owns 69,867 shares of the company’s stock valued at $113,000 after buying an additional 59,452 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of PMV Pharmaceuticals in the second quarter worth about $101,000. Finally, BML Capital Management LLC lifted its stake in shares of PMV Pharmaceuticals by 29.0% in the 3rd quarter. BML Capital Management LLC now owns 1,688,772 shares of the company’s stock valued at $2,516,000 after acquiring an additional 379,375 shares during the last quarter. 90.20% of the stock is owned by hedge funds and other institutional investors.

PMV Pharmaceuticals Stock Performance

PMVP stock opened at $1.50 on Friday. The stock has a market capitalization of $77.62 million, a price-to-earnings ratio of -1.50 and a beta of 1.47. The firm’s 50-day moving average price is $1.61 and its two-hundred day moving average price is $1.58. PMV Pharmaceuticals, Inc. has a 12-month low of $1.40 and a 12-month high of $3.47.

PMV Pharmaceuticals (NASDAQ:PMVP) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.02). Equities analysts predict that PMV Pharmaceuticals, Inc. will post -1.06 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, Oppenheimer upgraded PMV Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $6.00 price target on the stock in a research report on Friday, November 8th. Five equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, PMV Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $5.80.

PMV Pharmaceuticals Company Profile

PMV Pharmaceuticals, Inc, a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function.